TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00439907

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: End-to-end repair of the external anal sphincter muscle
Description: Surgical procedure: End-to-end repair of the external anal sphincter muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Overlap repair of the external anal sphincter muscle
Description: Surgical procedure: Overlap repair of the external anal sphincter muscle
Study: NCT03327688

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care ultrasound
Description: Point-of-care ultrasound performed by an emergency physician

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Point-of-care ultrasound
Description: Point-of-care ultrasound performed by an emergency physician
Study: NCT02619279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livelihood intervention
Description: Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
Study: NCT00752856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra + Isentress
Description: kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla 1 tab once a day
Study: NCT01942798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Description: Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wii Big Brain Academy Degree program
Description: Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
Study: NCT00386724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spinal Cord Stimulation System
Description: Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artisan Surgical Lead
Description: Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
Study: NCT04044846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity program for homebound older adults faciliated by Personal Support Workers
Description: The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
Study: NCT01082107

Intervention type: OTHER
Group type: OTHER
Intervention: Solar disinfection in transparent containers (plastic bottles)
Description: Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (\> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
Study: NCT02673671

Intervention type: DEVICE
Intervention: G-Tech Myoelectric recording device
Description: A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.

Intervention type: DEVICE
Intervention: G-Tech Myoelectric recording device
Description: A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
Study: NCT00288171

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule twice daily for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Allopurinol 200mg twice daily for one month
Study: NCT02883829

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Based Web-Based Health Information
Description: The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider-Based Web-Based Health Information
Description: The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
Study: NCT01489956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immucothel Alone (Part A)
Description: 100 ug at day 0 (priming dose) and day 9(booster dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immucothel+Montanide (Part A)
Description: 100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immucothel Alone or Immucothel+Montanide (Part B)
Description: 50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
Study: NCT03801837

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Macadamia Nut
Description: Participants will be provided with the appropriate portion of macadamia nuts \[15% of daily calories or 30-45 grams based on kcal requirement of the individual\]

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Diet
Description: Participants will continue with their Habitual Diet during this part of the intervention
Study: NCT03559764

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR T cells
Description: Transparent colorless or slightly yellow liquid
Study: NCT01473758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 µg tablet, od, oral administration in the morning after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, od, oral administration in the morning after breakfast
Study: NCT00192127

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FluMist
Description: A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
Study: NCT06185712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led disease management education
Description: Nurse-led disease management education was applied to the intervention group
Study: NCT02611752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: CAM2038 subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: CAM2038 subcutaneous injection
Study: NCT03422783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standardized tetanic stimulation
Description: The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Catastrophizing score
Description: Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nociceptive threshold
Description: Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biomarkers
Description: Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
Study: NCT01880710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy
Description: Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hysterectomy
Description: total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
Study: NCT03770871

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp treatment using Dycal (TM)
Description: Partial caries removal and protection of the dental pulp with biocompatible material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment using Dycal (TM)
Description: Partial caries removal and protection of the dental pulp with biocompatible material

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp treatment using Vitrebond (TM )
Description: Partial caries removal and protection of the dental pulp with biocompatible material

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment using Vitrebond (TM )
Description: Partial caries removal and protection of the dental pulp with biocompatible material
Study: NCT01264211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diacerein
Description: Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
Study: NCT01789281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR Depot
Description: Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
Study: NCT03070210

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-celiac ganglia block (EUS-CGB)
Description: The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: EUS-celiac plexus block (EUS-CPB)
Description: In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
Study: NCT01294592

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride plus tamsulosin
Description: Take 1 capsule daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Take 1 capsule daily when escalation criteria met
Study: NCT04457908

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: intelligent assessment
Description: intelligent neurological function assessment
Study: NCT05494944

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ThuLEP
Description: Minimal invasive prostate intervention
Study: NCT03401645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wrist Alarm
Description: Wrist device with alarm timer

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Home-based Arm and Hand Exercise
Description: Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Arm and Hand Exercise
Description: Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
Study: NCT00461630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER niacin/laropiprant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Description: 10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe/simvastatin
Description: 10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
Study: NCT02338323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
Study: NCT02097108

Intervention type: DRUG
Group type: OTHER
Intervention: Raltegravir
Study: NCT01475136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Study: NCT02032420

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ART
Study: NCT02351388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Study: NCT02511808

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Advice
Description: Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Motivational Interviewing
Description: Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Control Training
Description: Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
Study: NCT01670747

Intervention type: RADIATION
Intervention: Chest computed tomography
Study: NCT02578628

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Engagement
Description: The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
Study: NCT04389944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: convalescent plasma application to SARS-CoV-2 infected patients
Description: In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.
Study: NCT03011671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
Study: NCT04398394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellularis version 1 imaging
Description: Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellularis version 1 imaging
Description: Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellularis version 1 imaging
Description: Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellularis version 1 imaging
Description: Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellularis version 1 imaging
Description: Using a new modality for retinal cell imaging, we aim at comparing qualitatively and quantitatively, the morphology of the deepest layer of the retina, the retinal pigment epithelium (RPE) by imaging the people with a prototype instrument (Cellularis version 1).
Study: NCT03956433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-made pancakes enriched with docosahexaenoic acid (DHA)
Description: One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-made pancakes enriched with beta-glucan (BG)
Description: One portion of BG-enriched pancakes will be eaten each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-made pancakes enriched with anthocyanins (AC)
Description: One portion of AC-enriched pancakes will be eaten each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)
Description: One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)
Description: One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
Study: NCT00697112

Intervention type: DRUG
Intervention: Sirolimus
Description: Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
Study: NCT01438554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Study: NCT02198677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior to posterior pressures
Description: Anterior to posterior pressures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral glide
Description: Lateral glide
Study: NCT02579330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloshield
Description: Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.